Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Fort Worth, TX
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Houston, TX
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Longview, TX
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Longview, TX
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Hampton, VA
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Hampton, VA
Click here to add this to my saved trials
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Ponce,
Fosamprenavir Versus Other Protease Inhibitors
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Ponce,
Click here to add this to my saved trials
GSK1349572 Relative Bioavailability Study
Relative Bioavailability Study of Three Different Tablet Formulations of GSK1349572 50 mg and the Dose Proportionality of and Effect of Food on the Selected Formulation in Healthy Male and Female Volunteers (ING113674)
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from
Austin, TX
GSK1349572 Relative Bioavailability Study
Relative Bioavailability Study of Three Different Tablet Formulations of GSK1349572 50 mg and the Dose Proportionality of and Effect of Food on the Selected Formulation in Healthy Male and Female Volunteers (ING113674)
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
Status: Enrolling
Updated:  6/13/2017
Naval Medical Center - San Diego
mi
from
San Diego, CA
Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
Status: Enrolling
Updated: 6/13/2017
Naval Medical Center - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
Status: Enrolling
Updated:  6/13/2017
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
Status: Enrolling
Updated: 6/13/2017
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Hobson City, AL
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Hobson City, AL
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Los Angeles, CA
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
mi
from
Washington, D.C.,
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
mi
from
Washington, D.C.,
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Orlando, FL
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Atlanta, GA
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Macon, GA
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Macon, GA
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Chicago, IL
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Baltimore, MD
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Boston, MA
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Jackson, MS
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Saint Louis, MO
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Newark, NJ
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
New York, NY
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Huntersville, NC
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Huntersville, NC
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Dallas, TX
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated:  6/19/2017
Clinical Research Facility
mi
from
Houston, TX
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Status: Enrolling
Updated: 6/19/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
An Interactive Game for HIV Prevention in Early Adolescents
An Interactive Video Game for HIV Prevention in Early Adolescents
Status: Enrolling
Updated:  6/26/2017
Yale School of Medicine
mi
from
New Haven, CT
An Interactive Game for HIV Prevention in Early Adolescents
An Interactive Video Game for HIV Prevention in Early Adolescents
Status: Enrolling
Updated: 6/26/2017
Yale School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Neurocognitive Effects of Opiate Agonist Treatment
Neurocognitive Effects of Opiate Agonist Treatment
Status: Enrolling
Updated:  7/5/2017
Fordham University
mi
from
The Bronx, NY
Neurocognitive Effects of Opiate Agonist Treatment
Neurocognitive Effects of Opiate Agonist Treatment
Status: Enrolling
Updated: 7/5/2017
Fordham University
mi
from
The Bronx, NY
Click here to add this to my saved trials
Neurocognitive Effects of Opiate Agonist Treatment
Neurocognitive Effects of Opiate Agonist Treatment
Status: Enrolling
Updated:  7/5/2017
The Albert Einstein College of Medicine of Yeshiva University
mi
from
The Bronx, NY
Neurocognitive Effects of Opiate Agonist Treatment
Neurocognitive Effects of Opiate Agonist Treatment
Status: Enrolling
Updated: 7/5/2017
The Albert Einstein College of Medicine of Yeshiva University
mi
from
The Bronx, NY
Click here to add this to my saved trials
The Health Access and Recovery Peer Program
A Peer-Led, Medical Disease Self-Management Program for Mental Health Consumers
Status: Enrolling
Updated:  7/12/2017
Central Fulton Community Mental Health Center at Grady Hospital
mi
from
Atlanta, GA
The Health Access and Recovery Peer Program
A Peer-Led, Medical Disease Self-Management Program for Mental Health Consumers
Status: Enrolling
Updated: 7/12/2017
Central Fulton Community Mental Health Center at Grady Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Clinical Trial of SystemCHANGE to Improve Exercise, Diet and Health in HIV-Infected Adults
Status: Enrolling
Updated:  7/18/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
A Clinical Trial of SystemCHANGE to Improve Exercise, Diet and Health in HIV-Infected Adults
Status: Enrolling
Updated: 7/18/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
Health for Life Clinic Little Rock
mi
from
Little Rock, AR
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
Health for Life Clinic Little Rock
mi
from
Little Rock, AR
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
Quest Clinical Research
mi
from
San Francisco, CA
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
Quest Clinical Research
mi
from
San Francisco, CA
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
Infectious Disease Associats of NW Florida Center for Prevention and Treatment of Infections Infectious Diseases Associates of NW FL
mi
from
Pensacola, FL
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
Infectious Disease Associats of NW Florida Center for Prevention and Treatment of Infections Infectious Diseases Associates of NW FL
mi
from
Pensacola, FL
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
Rowan Tree Medical, P.A.
mi
from
Wilton Manors, FL
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
Rowan Tree Medical, P.A.
mi
from
Wilton Manors, FL
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
University of Iowa Departments of Internal Medicine and Microbiology University of Iowa
mi
from
Iowa City, IA
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
University of Iowa Departments of Internal Medicine and Microbiology University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
University of Pennsylvania Clinical Trials Unit
mi
from
Philadelphia, PA
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
University of Pennsylvania Clinical Trials Unit
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
Clinical Research Puerto Rico
mi
from
San Juan,
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
Clinical Research Puerto Rico
mi
from
San Juan,
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
Dupont Circle Physician's Group
mi
from
Washington, D.C.,
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
Dupont Circle Physician's Group
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated:  7/20/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Status: Enrolling
Updated: 7/20/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Effect of Repeated Exposures to Compressed Air on Patients With AIDS
Effect of Repeated Exposure to Compressed Air on Patients With AIDS (Acquired Immunodeficiency Syndrome)
Status: Enrolling
Updated:  7/26/2017
Detroit Receiving Hospital
mi
from
Detroit, MI
Effect of Repeated Exposures to Compressed Air on Patients With AIDS
Effect of Repeated Exposure to Compressed Air on Patients With AIDS (Acquired Immunodeficiency Syndrome)
Status: Enrolling
Updated: 7/26/2017
Detroit Receiving Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
GSK706769 Repeat Dose Study
A Double-Blind, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK706769 in Healthy Male and Female Subjects
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Madison, WI
GSK706769 Repeat Dose Study
A Double-Blind, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK706769 in Healthy Male and Female Subjects
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet
A Phase I, Single Dose, Five-period Crossover Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet as Compared to a Co-dose of TIVICAY and EPZICOM in Healthy Subjects
Status: Enrolling
Updated:  8/3/2017
GSK Investigational Site
mi
from
Overland Park, KA
Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet
A Phase I, Single Dose, Five-period Crossover Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet as Compared to a Co-dose of TIVICAY and EPZICOM in Healthy Subjects
Status: Enrolling
Updated: 8/3/2017
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 Monoclonal Antibody in HIV-infected and HIV-uninfected Individuals
Status: Enrolling
Updated:  8/7/2017
Rockefeller University
mi
from
New York, NY
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 Monoclonal Antibody in HIV-infected and HIV-uninfected Individuals
Status: Enrolling
Updated: 8/7/2017
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 Monoclonal Antibody in HIV-infected and HIV-uninfected Individuals
Status: Enrolling
Updated:  8/7/2017
University of Cologne
mi
from
Cologne,
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 Monoclonal Antibody in HIV-infected and HIV-uninfected Individuals
Status: Enrolling
Updated: 8/7/2017
University of Cologne
mi
from
Cologne,
Click here to add this to my saved trials
A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone
A Phase 1, Open-Label, Drug-Drug Interaction Study Between Methadone and BMS-663068; and Between Buprenorphine/Naloxone and BMS-663068
Status: Enrolling
Updated:  8/8/2017
GSK Investigational Site
mi
from
Orlando, FL
A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone
A Phase 1, Open-Label, Drug-Drug Interaction Study Between Methadone and BMS-663068; and Between Buprenorphine/Naloxone and BMS-663068
Status: Enrolling
Updated: 8/8/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone
A Phase 1, Open-Label, Drug-Drug Interaction Study Between Methadone and BMS-663068; and Between Buprenorphine/Naloxone and BMS-663068
Status: Enrolling
Updated:  8/8/2017
GSK Investigational Site
mi
from
Overland Park, KA
A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone
A Phase 1, Open-Label, Drug-Drug Interaction Study Between Methadone and BMS-663068; and Between Buprenorphine/Naloxone and BMS-663068
Status: Enrolling
Updated: 8/8/2017
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression
A Randomized Study to Evaluate the Effect of Switching From Efavirenz to Atazanavir/ Ritonavir on Lipoatrophy and Mitochondrial Dysfunction in HIV-infected Subjects With Good Virologic Suppression
Status: Enrolling
Updated:  8/10/2017
Cleveland Clinic
mi
from
Cleveland, OH
Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression
A Randomized Study to Evaluate the Effect of Switching From Efavirenz to Atazanavir/ Ritonavir on Lipoatrophy and Mitochondrial Dysfunction in HIV-infected Subjects With Good Virologic Suppression
Status: Enrolling
Updated: 8/10/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Maternal HIV: Trial to Assist Disclosure to Children
2/2-Maternal HIV: Multisite Trial to Assist Disclosure to Children
Status: Enrolling
Updated:  8/10/2017
Georgia State University
mi
from
Atlanta, GA
Maternal HIV: Trial to Assist Disclosure to Children
2/2-Maternal HIV: Multisite Trial to Assist Disclosure to Children
Status: Enrolling
Updated: 8/10/2017
Georgia State University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Measurement of Plasma and Intracellular Concentrations of Raltegravir
Measurement of Plasma and Intracellular Concentrations of Raltegravir in Patients Infected With Human Immunodeficiency Virus
Status: Enrolling
Updated:  8/16/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Measurement of Plasma and Intracellular Concentrations of Raltegravir
Measurement of Plasma and Intracellular Concentrations of Raltegravir in Patients Infected With Human Immunodeficiency Virus
Status: Enrolling
Updated: 8/16/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials